These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29343473)

  • 1. Smoking affects the interferon beta treatment response in multiple sclerosis.
    Petersen ER; Oturai AB; Koch-Henriksen N; Magyari M; Sørensen PS; Sellebjerg F; Søndergaard HB
    Neurology; 2018 Feb; 90(7):e593-e600. PubMed ID: 29343473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis.
    Petersen ER; Søndergaard HB; Laursen JH; Olsson AG; Börnsen L; Soelberg Sørensen P; Sellebjerg F; Bang Oturai A
    Mult Scler; 2019 Aug; 25(9):1298-1305. PubMed ID: 30070595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients.
    Samadzadeh S; Tabibian E; Sabokbar T; Shakoori A; Dehgolan SR; Armaki SA; Aslanbeigi B; Abolfazli R
    J Neurol Sci; 2015 May; 352(1-2):37-40. PubMed ID: 25824849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-beta and disability progression in relapsing-remitting multiple sclerosis.
    Drulovic J; Kostic J; Mesaros S; Dujmovic Basuroski I; Stojsavljevic N; Kisic-Tepavcevic D; Pekmezovic T
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S65-9. PubMed ID: 24321159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term disability outcomes in relapsing-remitting multiple sclerosis: a 10-year follow-up study.
    Drulovic J; Ivanovic J; Mesaros S; Martinovic V; Kisic-Tepavcevic D; Dujmovic I; Pekmezovic T
    Neurol Sci; 2019 Aug; 40(8):1627-1636. PubMed ID: 31011930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial.
    Massacesi L; Tramacere I; Amoroso S; Battaglia MA; Benedetti MD; Filippini G; La Mantia L; Repice A; Solari A; Tedeschi G; Milanese C
    PLoS One; 2014; 9(11):e113371. PubMed ID: 25402490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression ratio of matrix metalloproteinase-9 (MMP9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) RNA levels in Iranian multiple sclerosis patients.
    Nazdik MK; Taheri M; Sajjadi E; Arsang-Jang S; Koohpar ZK; Inoko H; Sayad A
    Hum Antibodies; 2016; 24(3-4):65-70. PubMed ID: 27689613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender effects on treatment response to interferon-beta in multiple sclerosis.
    Magyari M; Koch-Henriksen N; Laursen B; Sørensen PS
    Acta Neurol Scand; 2014 Dec; 130(6):374-9. PubMed ID: 25208455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group.
    Koch-Henriksen N; Sørensen PS
    Mult Scler; 2000 Jun; 6(3):172-5. PubMed ID: 10871828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
    Buck D; Andlauer TF; Igl W; Wicklein EM; Mühlau M; Weber F; Köchert K; Pohl C; Arnason B; Comi G; Cook S; Filippi M; Hartung HP; Jeffery D; Kappos L; Barkhof F; Edan G; Freedman MS; Montalbán X; Müller-Myhsok B; Hemmer B;
    Mult Scler; 2019 Apr; 25(4):565-573. PubMed ID: 29521573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up regulation of MMP9 gene expression in female patients with multiple sclerosis.
    Hamedani SY; Taheri M; Sajjadi E; Omrani MD; Mazdeh M; Arsang-Jang S; Panah AS; Sayad A
    Hum Antibodies; 2016; 24(3-4):59-64. PubMed ID: 28128762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulating effects of WT1 on interferon-β-vitamin D association in MS.
    Lin R; Taylor BV; Charlesworth J; van der Mei I; Blizzard L; Stewart N; Ponsonby AL; Dwyer T; Pittas F; Simpson S
    Acta Neurol Scand; 2015 Apr; 131(4):231-9. PubMed ID: 25312909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA genes as modifiers of response to IFN-β-1a therapy in relapsing-remitting multiple sclerosis.
    Mazdeh M; Taheri M; Sayad A; Bahram S; Omrani MD; Movafagh A; Inoko H; Akbari MT; Noroozi R; Hajilooi M; Solgi G
    Pharmacogenomics; 2016 Apr; 17(5):489-98. PubMed ID: 27020477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis.
    Limmroth V; Malessa R; Zettl UK; Koehler J; Japp G; Haller P; Elias W; Obhof W; Viehöver A; Meier U; Brosig A; Hasford J; Putzki N; Kalski G; Wernsdörfer C;
    J Neurol; 2007 Jan; 254(1):67-77. PubMed ID: 17273808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAILR1 (rs20576) and GRIA3 (rs12557782) are not associated with interferon-β response in multiple sclerosis patients.
    Jazireian P; Sasani ST; Assarzadegan F; Azimian M
    Mol Biol Rep; 2020 Dec; 47(12):9659-9665. PubMed ID: 33269432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New natural history of interferon-beta-treated relapsing multiple sclerosis.
    Trojano M; Pellegrini F; Fuiani A; Paolicelli D; Zipoli V; Zimatore GB; Di Monte E; Portaccio E; Lepore V; Livrea P; Amato MP
    Ann Neurol; 2007 Apr; 61(4):300-6. PubMed ID: 17444502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse Relation between MxA Gene Expression and Age in Multiple Sclerosis Patients Reveals a Gender Difference in Response to Interferon Therapy.
    Taheri M; Mirinezhad M; Omrani MD; Sajjadi E; Inoko H; Sayad A
    Iran J Allergy Asthma Immunol; 2017 Feb; 16(1):21-27. PubMed ID: 28417621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.